伴隨式診斷的共同研究及授權契約:2010年～2025年

"伴隨診斷合作與許可交易" 報告提供了對全球領先生物製藥公司達成的伴隨診斷交易的全面了解和前所未有的訪問管道。

本報告詳細介紹了2010年至2025年期間的伴隨診斷交易，並詳細分析了公司達成伴隨診斷交易的方式和原因。這些交易通常包含多個組成部分，從合作研發到成果商業化。

本報告涵蓋了合作、開發、研究和授權交易。

本報告全面列出了自2010年以來宣布的545項伴隨診斷交易。此外，報告還包含本公司及其合作夥伴向美國證券交易委員會提交的合約文件（如有）。

本報告的第一章介紹了伴隨診斷交易。

第1章為報告簡介。

第2章概述了自2010年以來伴隨診斷領域的交易活動。

第3章概述了自2010年以來的主要伴隨診斷交易。交易按交易金額列出。

第4章簡要概述了伴隨診斷交易中最活躍的25家公司，隨後提供了伴隨診斷交易的完整清單以及公開的交易文件。

第5章全面深入地回顧了自2010年1月以來宣布的所有伴隨診斷交易，並提供了公開的交易文件。

第6章全面深入地回顧了自2010年1月以來達成或宣布的伴隨診斷夥伴關係。本章按伴隨診斷技術類型組織。

本報告也包含大量圖表和數據，展現了自2010年以來伴隨診斷交易的趨勢和活動。

此外，報告還提供了一個全面的交易目錄，按公司A-Z、交易類型和治療目標進行整理。每個交易標題都透過網頁連結連結到線上交易記錄，方便使用者根據需要輕鬆存取每份交易文件（如有）。

主要的優點

"伴隨診斷中的合作與授權協議" 提供讀者以下主要優勢：

• 了解自2010年以來的交易趨勢
• 瀏覽伴隨診斷的共同開發與授權交易
• 基準分析 - 確定交易的市場價值
• 財務條款 - 一次性付款、里程碑付款、特許權使用費
• 依公司A-Z、交易類型及治療領域排列的交易目錄
• 主要交易價值
• 最活躍的交易撮合者
• 確定每筆交易的資產和交易條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款是否適合您的合作夥伴
• 節省數百小時的研究時間

調查範圍

• 合作與 "伴隨診斷許可協議" （ "伴隨診斷合作與許可協議" ）旨在深入了解全球領先生物製藥公司達成的伴隨診斷趨勢和交易結構。

伴隨診斷合作與授權協議包括：

• 生物製藥產業伴隨診斷交易趨勢
• 涵蓋製藥和生物技術的伴隨診斷交易記錄目錄
• 伴隨診斷領域的主要交易
• 最活躍的伴隨診斷許可公司
• "伴隨診斷合作與許可協議" 提供全面的交易記錄存取權限，包括合約文件（如有）。

分析合約有助於進行盡職調查：

• 授予或選擇的具體權利是什麼？
• 合約夥伴實際上被授予了什麼？
• 授予了哪些獨家權利？
• 合約的付款結構是怎樣的？
• 如何審計銷售和付款？
• 合約期限是多久？
• 合約的關鍵條款是如何定義的？
• 如何處理和歸屬知識產權？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密和資訊揭露？
• 如何解決爭議？
• 在什麼情況下可以終止合約？
• 如果所有權發生變更會發生什麼事？
• 已約定哪些分許可或分包條款？
• 公司堅持哪些樣板條款？
• 哪些樣板條款似乎因合作夥伴和交易類型而異？
• 該公司在合約法方面主張哪個司法管轄權？

目錄

摘要整理

第1章 簡介

第2章 伴隨式診斷的交易趨勢

• 簡介
• 多年的伴隨式診斷交易
• 最活躍的伴隨式診斷交易業者
• 伴隨式診斷交易，各交易類型
• 伴隨式診斷交易，各治療領域
• 伴隨式診斷交易，各業界
• 伴隨式診斷交易的交易條件
  • 伴隨式診斷交易的主要價值
  • 伴隨式診斷契約的預付款
  • 伴隨式診斷交易的里程金
  • 伴隨式診斷的權利金費率

第3章 -主要伴隨式診斷交易

• 簡介
• 主要的伴隨式診斷交易，各金額

第4章 -最活躍的伴隨式診斷的交易廠商

• 簡介
• 最活躍的伴隨式診斷交易業者
• 最活躍的伴隨式診斷交易的企業簡介

第5章 伴隨式診斷契約交易名錄

• 簡介
• 伴隨式診斷契約交易名錄

第6章 -各技術類型的伴隨式診斷交易

• 交易名錄
• 交易名錄- 伴隨式診斷交易，各企業
• 交易名錄- 伴隨式診斷交易，各交易類型
• 交易名錄- 伴隨式診斷交易，各治療領域
• 交易類型定義
• 關於調查公司
• 目前聯盟
• 目前契約
• 最近的報告標題

Companion Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the companion diagnostic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of companion diagnostic deals from 2010 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 545 companion diagnostic deals announced since 2010 including financial terms where available including links to online deal records of actual companion diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of companion diagnostic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2010.

Chapter 3 provides an overview of the leading companion diagnostic deals since 2010. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in companion diagnostic dealmaking with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of companion diagnostic deals signed and announced since Jan 2010, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of companion diagnostic partnering deals signed and announced since Jan 2010. The chapter is organized by specific companion diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in companion diagnostic deal making since 2010.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Companion Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2010
• Browse companion diagnostic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Companion Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of companion diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Companion Diagnostic Collaboration and Licensing Deals includes:

• Trends in companion diagnostic dealmaking in the biopharma industry
• Directory of companion diagnostic deal records covering pharmaceutical and biotechnology
• The leading companion diagnostic deals by value
• Most active companion diagnostic licensing dealmakers
• Companion Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in companion diagnostic dealmaking

• 2.1. Introduction
• 2.2. Companion diagnostic deals over the years
• 2.3. Most active companion diagnostic dealmakers
• 2.4. Companion diagnostic deals by deal type
• 2.5. Companion diagnostic deals by therapy area
• 2.6. Companion diagnostic deals by industry sector
• 2.7. Deal terms for companion diagnostic deals
  • 2.7.1 Companion diagnostic deals headline values
  • 2.7.2 Companion diagnostic deal upfront payments
  • 2.7.3 Companion diagnostic deal milestone payments
  • 2.7.4 Companion diagnostic royalty rates

Chapter 3 - Leading companion diagnostic deals

• 3.1. Introduction
• 3.2. Top companion diagnostic deals by value

Chapter 4 - Most active companion diagnostic dealmakers

• 4.1. Introduction
• 4.2. Most active companion diagnostic dealmakers
• 4.3. Most active companion diagnostic deals company profiles

Chapter 5 - Companion diagnostic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Companion diagnostic contracts dealmaking directory

Chapter 6 - Companion diagnostic dealmaking by technology type

• Deal directory
• Deal directory - Companion diagnostic deals by company A-Z
• Deal directory - Companion diagnostic deals by deal type
• Deal directory - Companion diagnostic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Companion diagnostic deals since 2016
• Figure 2: Active companion diagnostic dealmaking activity - 2016 - 2025
• Figure 3: Companion diagnostic deals by deal type since 2016
• Figure 4: Companion diagnostic deals by therapy area since 2016
• Figure 5: Companion diagnostic deals by industry sector since 2016
• Figure 6: Companion diagnostic deals with a headline value
• Figure 7: Companion diagnostic deals with an upfront value
• Figure 8: Companion diagnostic deals with a milestone value
• Figure 9: Companion diagnostic deals with a royalty rate value
• Figure 10: Top companion diagnostic deals by value since 2016
• Figure 11: Most active companion diagnostic dealmakers 2016 - 2025
• Figure 12: Companion diagnostic deals by technology type since 2016